Immunome Inc Financials
This page shows Immunome Inc (IMNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Immunome Inc has an operating margin of -3228.8%, meaning the company retains $-3229 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -3382.4% the prior year.
Immunome Inc's revenue declined 23.2% year-over-year, from $9.0M to $6.9M. This contraction results in a growth score of 0/100.
Immunome Inc carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 14.69, Immunome Inc holds $14.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Immunome Inc generated -$190.9M in operating cash flow, capex of $9.7M consumed most of it, leaving -$200.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Immunome Inc generates a -33.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -161.7% the prior year.
Immunome Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Immunome Inc generates $0.90 in operating cash flow (-$190.9M OCF vs -$212.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Immunome Inc earns $-19.1 in operating income for every $1 of interest expense (-$224.1M vs $11.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Immunome Inc generated $6.9M in revenue in fiscal year 2025. This represents a decrease of 23.2% from the prior year.
Immunome Inc's EBITDA was -$221.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.1% from the prior year.
Immunome Inc reported -$212.4M in net income in fiscal year 2025. This represents an increase of 27.5% from the prior year.
Immunome Inc earned $-2.43 per diluted share (EPS) in fiscal year 2025. This represents an increase of 51.4% from the prior year.
Cash & Balance Sheet
Immunome Inc generated -$200.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 70.1% from the prior year.
Immunome Inc held $653.5M in cash against $0 in long-term debt as of fiscal year 2025.
Immunome Inc had 113M shares outstanding in fiscal year 2025. This represents an increase of 75.5% from the prior year.
Margins & Returns
Immunome Inc's operating margin was -3228.8% in fiscal year 2025, reflecting core business profitability. This is up 153.5 percentage points from the prior year.
Immunome Inc's net profit margin was -3060.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 180.4 percentage points from the prior year.
Immunome Inc's ROE was -33.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 128.2 percentage points from the prior year.
Capital Allocation
Immunome Inc invested $177.3M in research and development in fiscal year 2025. This represents an increase of 36.9% from the prior year.
Immunome Inc invested $9.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 35.0% from the prior year.
IMNM Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $4.0M+37.2% | $2.9M+6.9% | $2.7M-5.9% | $2.9M+23.1% | $2.4M+129.7% | $1.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $49.2M+21.6% | $40.5M+9.7% | $36.9M-23.0% | $47.9M+28.7% | $37.2M+27.9% | $29.1M+89.2% | $15.4M |
| SG&A Expenses | N/A | $10.9M+9.0% | $10.0M-6.1% | $10.7M+2.3% | $10.4M+9.7% | $9.5M+36.5% | $7.0M+16.2% | $6.0M |
| Operating Income | N/A | -$60.1M-29.4% | -$46.5M-4.1% | -$44.6M+46.2% | -$83.0M-64.2% | -$50.5M-26.3% | -$40.0M+69.8% | -$132.3M |
| Interest Expense | N/A | $2.7M-13.0% | $3.1M+2.8% | $3.0M+10.1% | $2.7M-20.5% | $3.4M-12.0% | $3.9M+38.5% | $2.8M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$57.5M-32.4% | -$43.4M-4.2% | -$41.6M+48.1% | -$80.2M-70.4% | -$47.1M-30.4% | -$36.1M+72.1% | -$129.5M |
| EPS (Diluted) | N/A | $-0.65-30.0% | $-0.50+3.8% | $-0.52 | N/A | $-0.78-30.0% | $-0.60+76.1% | $-2.51 |
IMNM Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $683.2M+128.2% | $299.4M+1.0% | $296.3M-13.5% | $342.7M+42.6% | $240.2M-6.5% | $256.9M-13.3% | $296.2M-7.4% | $319.8M |
| Current Assets | $660.8M+136.1% | $279.9M+0.9% | $277.4M-14.1% | $323.1M+46.0% | $221.3M-9.3% | $244.0M-14.2% | $284.3M-9.3% | $313.3M |
| Cash & Equivalents | $653.5M+139.7% | $272.6M+89.5% | $143.9M-44.2% | $257.6M+79.7% | $143.4M-7.9% | $155.6M-5.9% | $165.3M-38.7% | $269.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $48.8M+37.8% | $35.5M+31.2% | $27.0M-24.0% | $35.6M-39.8% | $59.1M+40.7% | $42.0M-0.9% | $42.4M+24.0% | $34.2M |
| Current Liabilities | $45.0M+43.1% | $31.4M+37.4% | $22.9M-25.7% | $30.8M-43.3% | $54.3M+37.4% | $39.5M-0.9% | $39.9M+29.7% | $30.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $634.3M+140.4% | $263.9M-2.0% | $269.3M-12.3% | $307.1M+69.5% | $181.2M-15.7% | $214.9M-15.3% | $253.8M-11.1% | $285.6M |
| Retained Earnings | -$728.2M-10.6% | -$658.3M-9.6% | -$600.8M-7.8% | -$557.4M-8.1% | -$515.8M-18.4% | -$435.5M-12.1% | -$388.4M-10.3% | -$352.3M |
IMNM Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$48.0M-18.4% | -$40.5M+18.0% | -$49.4M+6.9% | -$53.1M-26.1% | -$42.1M-23.1% | -$34.2M-46.0% | -$23.4M-109.5% | -$11.2M |
| Capital Expenditures | $4.0M+258.3% | $1.1M+23.3% | $905K-75.3% | $3.7M+225.5% | $1.1M-26.8% | $1.5M-34.3% | $2.3M+8.3% | $2.2M |
| Free Cash Flow | -$52.0M-24.8% | -$41.6M+17.3% | -$50.3M+11.3% | -$56.7M-31.3% | -$43.2M-20.9% | -$35.7M-38.7% | -$25.7M-93.0% | -$13.3M |
| Investing Cash Flow | -$4.0M-103.2% | $123.9M+293.1% | -$64.2M-1361.0% | $5.1M-47.8% | $9.8M-59.5% | $24.1M+129.5% | -$81.7M-119.4% | -$37.2M |
| Financing Cash Flow | $432.8M+853.5% | $45.4M+82625.5% | -$55K-100.0% | $162.2M+707.7% | $20.1M+6485.2% | $305K-56.1% | $694K-99.7% | $219.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IMNM Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -1157.6%+367.9pp | -1525.5%+1504.8pp | -3030.3%-1294.2pp | -1736.1%-43.7pp | -1692.4%+11164.6pp | -12857.1% |
| Net Margin | N/A | N/A | -1080.9%+342.2pp | -1423.1%+1507.8pp | -2930.9%-1312.4pp | -1618.6%-90.6pp | -1528.0%+11056.3pp | -12584.3% |
| Return on Equity | N/A | -21.8%-5.6pp | -16.1%-2.6pp | -13.6%+30.7pp | -44.3%-22.4pp | -21.9%-7.7pp | -14.2%+31.1pp | -45.3% |
| Return on Assets | N/A | -19.2%-4.5pp | -14.6%-2.5pp | -12.2%+21.3pp | -33.4%-15.1pp | -18.3%-6.1pp | -12.2%+28.3pp | -40.5% |
| Current Ratio | 14.69+5.8 | 8.90-3.2 | 12.13+1.6 | 10.49+6.4 | 4.08-2.1 | 6.17-1.0 | 7.12-3.1 | 10.18 |
| Debt-to-Equity | 0.08-0.1 | 0.13+0.0 | 0.10-0.0 | 0.12-0.2 | 0.33+0.1 | 0.20+0.0 | 0.17+0.0 | 0.12 |
| FCF Margin | N/A | N/A | -1253.0%+685.5pp | -1938.5%-361.2pp | -1577.3%-350.3pp | -1227.0%-138.1pp | -1088.9%+206.9pp | -1295.8% |
Similar Companies
Frequently Asked Questions
What is Immunome Inc's annual revenue?
Immunome Inc (IMNM) reported $6.9M in total revenue for fiscal year 2025. This represents a -23.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Immunome Inc's revenue growing?
Immunome Inc (IMNM) revenue declined by 23.2% year-over-year, from $9.0M to $6.9M in fiscal year 2025.
Is Immunome Inc profitable?
No, Immunome Inc (IMNM) reported a net income of -$212.4M in fiscal year 2025, with a net profit margin of -3060.0%.
What is Immunome Inc's EBITDA?
Immunome Inc (IMNM) had EBITDA of -$221.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immunome Inc's operating margin?
Immunome Inc (IMNM) had an operating margin of -3228.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Immunome Inc's net profit margin?
Immunome Inc (IMNM) had a net profit margin of -3060.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Immunome Inc's return on equity (ROE)?
Immunome Inc (IMNM) has a return on equity of -33.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immunome Inc's free cash flow?
Immunome Inc (IMNM) generated -$200.6M in free cash flow during fiscal year 2025. This represents a -70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immunome Inc's operating cash flow?
Immunome Inc (IMNM) generated -$190.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Immunome Inc's total assets?
Immunome Inc (IMNM) had $683.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immunome Inc's capital expenditures?
Immunome Inc (IMNM) invested $9.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immunome Inc spend on research and development?
Immunome Inc (IMNM) invested $177.3M in research and development during fiscal year 2025.
What is Immunome Inc's current ratio?
Immunome Inc (IMNM) had a current ratio of 14.69 as of fiscal year 2025, which is generally considered healthy.
What is Immunome Inc's debt-to-equity ratio?
Immunome Inc (IMNM) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Immunome Inc's return on assets (ROA)?
Immunome Inc (IMNM) had a return on assets of -31.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immunome Inc's cash runway?
Based on fiscal year 2025 data, Immunome Inc (IMNM) had $653.5M in cash against an annual operating cash burn of $190.9M. This gives an estimated cash runway of approximately 41 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Immunome Inc's Piotroski F-Score?
Immunome Inc (IMNM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immunome Inc's earnings high quality?
Immunome Inc (IMNM) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Immunome Inc cover its interest payments?
Immunome Inc (IMNM) has an interest coverage ratio of -19.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Immunome Inc?
Immunome Inc (IMNM) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.